论文部分内容阅读
目的观察重组人表皮生长因子结合硫辛酸对糖尿病足患者的疗效和安全性。方法选取了74例糖尿病足患者按照随机数字表发为观察组和对照组,各37例。其中对照组给于基础治疗,而观察组患者在此基础上给予了基因重组人表皮生长因子外用溶液,两组的治疗过程为7 h。结果治疗之后,两组患者溃疡面积全都有一定的缩小,然而观察组相对对照组来说有改善的程度更为明显,均差异有统计学意义(P<0.05)。而不良反应发生率作比较两组差异无统计学意义(P>0.05)。结论基因重组人表皮生长因子结合硫辛酸治疗糖尿病足的临床效果比较好,并且安全性性比较好。
Objective To observe the efficacy and safety of recombinant human epidermal growth factor combined with lipoic acid in patients with diabetic foot. Methods 74 patients with diabetic foot were randomly divided into observation group and control group, 37 cases in each group. The control group was given basic treatment, and the observation group received gene recombinant human epidermal growth factor topical solution on this basis. The treatment course of the two groups was 7 h. Results After treatment, the ulcer area of both groups all reduced to a certain extent. However, the improvement degree of the observation group was more obvious than that of the control group, with significant difference (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The clinical effect of recombinant human epidermal growth factor combined with lipoic acid in the treatment of diabetic foot is good and the safety is good.